Part 3 of this series for Global Biosimilars Week, penned by Dracey Poore, director of biosimilars at Cardinal Health, ...

Part 2 of this series for Global Biosimilars Week dives into the complexities of payer and pharmacy benefit manager (PBM) ...

Biosimilars hold the potential to dramatically lower health care costs and improve access to life-changing treatments, but ...

Part 1 of this 3-part series for Global Biosimilars Week focuses on legal barriers to biosimilar access in the US, including the patent system, and discusses ongoing legislative efforts to address ...

Phase 3 Study Reports Similar Efficacy Between SB17, Stelara in Psoriasis ...

Phase 3 Study Reports Similar Efficacy Between SB17, Stelara in Psoriasis ...

Sophia Humphreys, PharmD, MHA, BCBBS, director of system formulary management at Sutter Health, discusses how integrated delivery networks (IDNs) can help drive biosimilar adoption.

Phase 3 Study Reports Similar Efficacy Between SB17, Stelara in Psoriasis ...

Phase 3 Study Reports Similar Efficacy Between SB17, Stelara in Psoriasis ...

Phase 3 Study Reports Similar Efficacy Between SB17, Stelara in Psoriasis ...

A review article on tumor necrosis factor (TNF)-α inhibitors in inflammatory bowel disease (IBD) outlined current use of anti-TNF originators and biosimilars, their efficacy and safety, the benefits ...